#TumorBoardTuesday
1/3 CASE: 35 y/o F w stage 4 (diffuse supraclav/RP M1 LNs) GEJ AC, HER2 IHC3+, PD on 1L FOLFOX-trastuzumab after ~12m w new lung&peritoneal dz. Repeat EGD w bx: HER2 IHC3+/CPS 0. ctDNA profile NO HER2 amp (TP53 mt MAF 9.3%).
How would u treat this pt now?
1/3 CASE: 35 y/o F w stage 4 (diffuse supraclav/RP M1 LNs) GEJ AC, HER2 IHC3+, PD on 1L FOLFOX-trastuzumab after ~12m w new lung&peritoneal dz. Repeat EGD w bx: HER2 IHC3+/CPS 0. ctDNA profile NO HER2 amp (TP53 mt MAF 9.3%).
How would u treat this pt now?
https://twitter.com/tumorboardtues/status/1358755663493660672
#TumorBoardTuesday
2/3 CASE:35 y/o F w stage 4 (diffuse supraclav/RP M1 LNs) GEJ AC, HER2 IHC3+, PD on 1L FOLFOX-trastuzumab after ~12m w new lung&peritoneal dz. Repeat EGD w bx: HER2 IHC3+/CPS 0. ctDNA PROFILE w/o HER2 amp (TP53 mt MAF 9.3%). PS0
How would u treat this pt now?
2/3 CASE:35 y/o F w stage 4 (diffuse supraclav/RP M1 LNs) GEJ AC, HER2 IHC3+, PD on 1L FOLFOX-trastuzumab after ~12m w new lung&peritoneal dz. Repeat EGD w bx: HER2 IHC3+/CPS 0. ctDNA PROFILE w/o HER2 amp (TP53 mt MAF 9.3%). PS0
How would u treat this pt now?
3/3: Here’s a f/u related POLL:
Currently my preferred line to use trastuzumab-deruxtecan is:
Currently my preferred line to use trastuzumab-deruxtecan is:
@pashtoonkasi @GIcancerDoc @DrBonillaOnc @CathyEngMD @koaeraser @ECActionNetwork @myESMO @eirinipec @FlavioRochaMD @FilippoPietran4 @LFerri123 @mgfakih @agrothey @GI_OncologyHub @DrGarridoOncoGI @HH_Oncodr @TedHong9 @ILSONDavid @YJanjigianMD @Marindoc @KlempnerSam @KoheiShitara
@marklewismd @Labrat3 @NataliyaUboha @OncLive @OncoAlert @rutikamehtaMD @DrR_DUNNE @rcarvalhoonco @RussellPetty19 @rachnatshroff @RenoHemonc @KlempnerSam @Thalcin @TargetedOnc @mgibson21212 @practiceupdate @benweinbergmd @BenWestphalen @SteveMaronMD @mdmanishshah @SyedMAhmedMDPhD
Tweetorial coming in 1 minute!!!!!! 🥳🤗
Wow 1st line!!!!
• • •
Missing some Tweet in this thread? You can try to
force a refresh
